Sutro Biopharma (NASDAQ:STRO) Shares Up 0.6% - Should You Buy?

Key Points

• Sutro Biopharma shares increased by 0.6% to $0.81, with trading volume significantly down at 233,544 shares compared to the average of 483,404.
• Recent analyst ratings show a mixed outlook, with price targets ranging from $0.80 (underperform) to $2.00 (overweight), while the consensus rating is currently a "Hold" with a target of $6.11.
• The company reported a loss of ($0.91) EPS, missing estimates while generating revenue of $17.4 million, surpassing expectations.

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report)'s share price rose 0.6% on Friday . The company traded as high as $0.85 and last traded at $0.81. Approximately 233,544 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 483,404 shares. The stock had previously closed at $0.81.

Analyst Ratings Changes

STRO has been the subject of several research analyst reports. Piper Sandler upgraded shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 target price for the company in a research note on Monday, June 16th. HC Wainwright restated a "neutral" rating and issued a $2.00 price objective on shares of Sutro Biopharma in a research note on Tuesday, April 29th. Finally, Bank of America dropped their price objective on shares of Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating for the company in a research note on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $6.11.

Sutro Biopharma Trading Down 1.0%

The company has a market cap of $67.99 million, a P/E ratio of -0.27 and a beta of 1.66. The firm's 50 day moving average price is $0.82 and its 200-day moving average price is $1.06.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.91) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.28). The firm had revenue of $17.40 million during the quarter, compared to analyst estimates of $11.61 million. Sutro Biopharma had a negative net margin of 373.66% and a negative return on equity of 347.60%. Analysts predict that Sutro Biopharma, Inc. will post -2.92 earnings per share for the current fiscal year.

Institutional Trading of Sutro Biopharma

Hedge funds have recently bought and sold shares of the stock. Cerity Partners LLC acquired a new stake in Sutro Biopharma during the 1st quarter worth approximately $25,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Sutro Biopharma in the fourth quarter valued at $26,000. Vontobel Holding Ltd. grew its stake in shares of Sutro Biopharma by 100.0% in the first quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company's stock valued at $33,000 after buying an additional 25,000 shares in the last quarter. CWM LLC grew its stake in shares of Sutro Biopharma by 73.2% in the second quarter. CWM LLC now owns 56,657 shares of the company's stock valued at $40,000 after buying an additional 23,941 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Sutro Biopharma by 174.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 60,617 shares of the company's stock worth $43,000 after purchasing an additional 38,561 shares during the period. 96.99% of the stock is currently owned by institutional investors and hedge funds.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.